TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06887803: A Phase I/II Open-Label, Multi-centre Study to Assess the Safety and Tolerability of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to an Approved JAK Inhibitors (HEM

Sponsor: iOnctura · Phase: PHASE1/PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 26 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$351,900

Rescue Site Savings

+$234,600

Unlock Full NCT06887803 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06887803 Rescue Dossier →